Navigation Links
Biotech Posts Weak Performance in April
Date:5/3/2010

SAN FRANCISCO, May 3 /PRNewswire/ -- Despite the pop in the shares of Dendreon on the announcement that its prostate cancer therapy Provenge had finally been approved by the FDA, the biotech sector failed to build on that event and turned in a lackluster performance for the month with the Burrill Biotech Select Index dropping 2 percent in April. Not helping the cause was the fact that several companies including Amgen and Gilead Sciences cut their profit forecasts citing the impact of costs from U.S. healthcare reform in their outlooks. Gilead closed the month down almost 13 percent. Although the company reported a 45 percent jump in quarterly profit it lowered its full-year revenue forecast due to the recently passed health care reform legislation. They said its impact will be felt mostly in the company's HIV treatment business. Amgen, whose shares fell 3.6 percent in April, estimated that going forward, healthcare reform would trim annual U.S. sales revenue by 5 percent to 6 percent and $200 million to $250 million this year.

The new U.S. healthcare law calls on drug companies to offer higher price rebates for government funded health plans and will eventually require them to pay a fee based on their market share of the public plans. Some of the changes went into effect at the beginning of the year and all will be phased in by January 1, 2014.

"The industry convenes in Chicago this week for BIO 2010, where over 18,000 delegates from around the world are expected to attend, and despite April's performance of the 'blue-chip biotech companies, the sector is certainly in much better shape than it was one year ago when BIO 2009 was held in Atlanta," said G. Steven Burrill,
'/>"/>

SOURCE Burrill & Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
2. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
3. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
4. CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum
5. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
6. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
7. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
8. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
9. Hawaii Biotech Receives Allowance to Perform West Nile Vaccine Clinical Trials
10. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
11. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Spanien, September 2, 2014 /PRNewswire/ ... auf dem ESC-Kongress 2014 präsentierte GARFIELD-AF-Register ... und Behandlungsergebnisse von schlaganfallgefährdeten Patienten in ... Die Daten der ... einer innovativen und unabhängigen Forschungsinitiative zur ...
(Date:9/2/2014)... -- Donald Spector , a renowned celebrated entrepreneur ... a Wearable Biosensor, which will issue today, September 2, ... Mr. Spector holds some of the earliest patents in ... by New York College of Health Professions, which has ... intellectual properties.  New York College noted that the Wearable ...
(Date:9/2/2014)... , Sept. 2, 2014  Avanir Pharmaceuticals, Inc. (NASDAQ: ... an overview of the company at the Morgan Stanley Global ... , Presentation date: Tuesday September 9, 2014 , ... live webcast and 30-day archive of this presentation will be ... Pharmaceuticals, Inc. Avanir Pharmaceuticals, Inc. is a biopharmaceutical ...
Breaking Medicine Technology:Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 2Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 3Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 4Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 5Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 6Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 7Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 8Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 9Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 10Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 11Wearable Biosensor Patent, the Grandfather of Wearable Biosensor Transmission Patents, Granted to Donald Spector, One of the Most Prolific Living Inventors in the World 2Wearable Biosensor Patent, the Grandfather of Wearable Biosensor Transmission Patents, Granted to Donald Spector, One of the Most Prolific Living Inventors in the World 3Wearable Biosensor Patent, the Grandfather of Wearable Biosensor Transmission Patents, Granted to Donald Spector, One of the Most Prolific Living Inventors in the World 4Wearable Biosensor Patent, the Grandfather of Wearable Biosensor Transmission Patents, Granted to Donald Spector, One of the Most Prolific Living Inventors in the World 5
... historic open letter to the World Health Organization ... Drugs (CoMeD) , and the United Methodist Women are seeking ... vaccines.  Currently, the mercury-based preservative Thimerosal, which is 49% mercury ... much of the world, despite the fact that it is ...
... Texas, March 15, 2012  OxySure® Systems, Inc. (OTCBB: ... emergency oxygen solutions with its "oxygen from powder" ... a Supplier Agreement ("Agreement") with W.W. Grainger, Inc. ... (Logo:  http://photos.prnewswire.com/prnh/20120315/DA71084LOGO ) In terms ...
Cached Medicine Technology:Global Call for Mercury-free Vaccines Issued 2OxySure Systems Announces Supplier Agreement With Grainger 2OxySure Systems Announces Supplier Agreement With Grainger 3
(Date:9/2/2014)... Today, Therapy Changes released ... Me?” The guide outlines common questions an individual may ... to common types of groups an individual can attend. ... the interventions of the therapist, but also from observing ... members,” says Rochelle Perper, Ph.D. and founder of Therapy ...
(Date:9/2/2014)... Friendship Village of Schaumburg is proud ... a contemporary marketing presence and visually solidifies the ... Friendship Senior Options,” said Stephen A. Yenchek, president ... the logo, we are making sure that our ... their families.” , Friendship Village is a retirement ...
(Date:9/2/2014)... 2, 2014 (HealthDay News) -- Complications are rare ... reconstruction, a new study indicates. However, the ... associated with a slightly higher risk for certain ... included more than 18,000 breast cancer patients who ... mastectomy with breast reconstruction and were followed for ...
(Date:9/2/2014)... return to the emergency department within a few days of ... symptoms and have lost trust in other parts of the ... published online today in Annals of Emergency Medicine ... ). , "When asked why they did not ... symptoms were too severe to wait until their scheduled appointment ...
(Date:9/2/2014)... Sept. 2, 2014 (HealthDay News) -- Two new studies ... suggests that 6-year-olds who were breast-fed have a lower ... bottle-fed infants, while the other finds a similar trend ... the "many benefits of breast-feeding in the immediate newborn ... Hill Hospital in New York City. She was not ...
Breaking Medicine News(10 mins):Health News:Friendship Village of Schaumburg In Illinois Announces New Logo 2Health News:Complication Rates Low With Mastectomy, Breast Reconstruction: Study 2Health News:Discharged patients return to the ER because 'better safe than sorry' 2Health News:More Evidence Breast-Feeding Lowers Child's Risk of Infections, Allergies 2
... cancer-prevention gene in the response to drug treatment for childhood ... known as the guardian of the genome, is known for ... gene are associated with a high incidence of cancer due ... tumours. , In childhood cancers such as neuroblastoma, p53 mutations ...
... tuning out distractions can be learned , MONDAY, Nov. ... a person,s brain is organized, says a U.S. study that ... training. , All the participants were between the ages of ... than 10 years experience as a band or orchestra director ...
... FDA says clotting drug poses increased death risk, while company ... (HealthDay News) -- Bayer AG suspended worldwide sales of Trasylol, ... on Monday following a request from the U.S. Food and ... for safety reasons. , The FDA cannot identify a patient ...
... HONG KONG, Nov. 5 Mass Financial Corp. ... a lawsuit in the Supreme Court of,British Columbia, ... for breach of contract and contract interference. In ... Michael Smith, President of MASS said the ...
... Inc. (Nasdaq: ALTH ) today reported financial results for ... 30, 2007, the,Company reported a net loss of $9.3 million, ... $8.1 million, or ($0.15) per share, for the third,quarter of ... Company,reported a net loss of $28.1 million, or ($0.43) per ...
... 5 Hooper Holmes,Inc. (AMEX: HH ) announced ... after-market on Thursday, November 8, 2007. The Company,will host ... 11:00 a.m.,Eastern Time. To participate in the third ... Hooper Holmes. A live web cast,will be hosted on ...
Cached Medicine News:Health News:Training, Experience Can Change How Brains Work 2Health News:Trasylol Pulled From Worldwide Market 2Health News:Trasylol Pulled From Worldwide Market 3Health News:Trasylol Pulled From Worldwide Market 4Health News:Mass Financial Corp. Launches Lawsuit Against Elekta AB, Seeks Substantial Damages 2Health News:Allos Therapeutics Reports Third Quarter 2007 Financial Results 2Health News:Allos Therapeutics Reports Third Quarter 2007 Financial Results 3Health News:Allos Therapeutics Reports Third Quarter 2007 Financial Results 4Health News:Allos Therapeutics Reports Third Quarter 2007 Financial Results 5Health News:Allos Therapeutics Reports Third Quarter 2007 Financial Results 6Health News:Allos Therapeutics Reports Third Quarter 2007 Financial Results 7Health News:Hooper Holmes Announces Third Quarter Earnings Release Date and Conference Call Information 2
Battery operated single speed motorized handpiece, tip cover, supplied with 0.5 mm tungsten burr (E0815 0.5) and one battery size "AA"....
5.5 mm disk shape burr. Diamond coated tip. Use with E0824 B handle....
Taper with blunt tip. Stainless steel. Round knurled handle with polished finish. Taper : Long 32 mm. Overall length: 3.9 inches. Most popular size or model....
One end with needle point and other end with medium taper. Stainless steel. Round knurled handle with polished finish. Overall length: 5.7 inches....
Medicine Products: